Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by deanthebeanon Feb 18, 2020 9:53pm

54 Views

Post# 30705987

RE:RE:Trading today

Pretty sure based on what? The price drop was not based on the saltzman selling as this transaction still needs approval and I expect that we should see a news release about that soon. Also, the daily volume was nothing extraordinary. I took this as a buying opportunity, snatching a chunk of the warrants for .01. There was a point near the end of the session where the bid was .005 and the ask was .01, I haven’t seen that for a while.

Bullboard Posts

Visionstate set to leverage success in the U.S. market